🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in the Netherlands / NCT05670938
Recruiting Observational

Follow-up After Surgery for Testicular Cancer

NCT05670938 · tracked via the Priya Life Science Netherlands tracker
Phase
Observational
Started
2022-11-30
Last updated
2023-02-23

Condition(s) studied

Testicular CancerTesticular Germ Cell TumorQuality of Life

Study summary

The currently developed implementation study aims to evaluate if a patient-led home-based follow-up approach is successful, improves quality of life, reduces anxiety and lessens fear of cancer recurrence during the years after treatment of certain types of testicular cancer.

Eligibility

Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years. * Histologically confirmed testicular cancer without distant metastasis and treated with curative intent less than 3 months ago: 1\. Non-seminomatous germ cell tumours, stage I low risk: * No lymphadenopathy or metastases on the postoperative scan. * Three consecutive blood drawings with normal tumour markers. * Patients undergoing lymph node dissection as a second curative operation after an orchiectomy, can also be included in case that the postoperative scan shows no residual disease or metastases. 2\. Non-seminomatous germ cell tumours, stage I high risk: * After completion of one cycle of Bleomycin, etoposide and platinum (BEP). * Biochemical remission at completion of chemotherapy, meaning three consecutive blood drawings with normal tumour markers. * No lymphadenopathy or metastases on the CT scan after completion of chemotherapy. 3\. Seminomatous or non-seminomatous germ cell tumours (after chemotherapy) with complete remission. * Biochemical remission at completion of chemotherapy, meaning three consecutive blood drawings with normal tumour markers. * No lymphadenopathy or metastases on the CT scan after completion of chemotherapy. * Scheduled or currently undergoing postoperative surveillance according to national and European guidelines. * Signed informed consent. Exclusion Criteria: * Patients with aberrant levels of LDH preoperatively (LDH \>248 U/L). * Patients enrolled in other studies that require strict adherence to any specific follow-up practice with regular imaging - yearly or more frequent - of the abdomen and/or thorax * Patients with comorbidity or other malignancy that requires imaging of the abdomen and/or thorax every year or more frequent * Inability to complete the questionnaires due to illiteracy and/or insufficient proficiency of the Dutch language

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Erasmus Medical Center Rotterdam South Holland Recruiting

More Erasmus Medical Center trials in the Netherlands

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05670938 on ClinicalTrials.gov ↗ ← All trials in the Netherlands